Clinical Research

HOME > R&D Achievement > Clinical Research > Article
 
DATE : 16-03-14 14:41
Clinical Outcome Comparison of Everolimus- and Biolimus-eluting Stents in Patients with Acute Myocardial Infarction.
 WRITER : stent
HIT : 1,361  
   C175._Korean_J_Med._2015;89_4_418-427..pdf (456.4K) [0] DATE : 2016-03-14 14:41:51
C175. Park IC, Jeong MH, Kim IS, Rhee JA, Choi JS, Park IH, Chai LS, Jeong YA, Hyun DY, Jeong HC, Lee KH, Park KH, Sim DS, Kim KH, Hong YJ, Park HU, Kim JH, Ahn YK, Cho JG, Park JC; Clinical Outcome Comparison of Everolimus- and Biolimus-eluting Stents in Patients with Acute Myocardial Infarction. Korean J Med. 2015;89(4)418-427.

(Abstract)
Background/Aims:
We compared the efficacy and safety of the second-generation everolimus-eluting stent (EES) and the third generation biolimus-eluting stent (BES) in patients with acute myocardial infarction (AMI).
Methods:
We analyzed 629 consecutive patients (mean age 65.1 ± 11.2 years, 426 males) with AMI undergoing percutaneous coronary intervention from February 2008 to April 2012. They were divided into two groups according to stent type (EES group, n = 426; BES group, n = 203). The primary end-point was 2-year major adverse cardiac events (MACEs), defined as the composite of all-cause death, myocardial infarction, target vessel revascularization, non-target vessel revascularization and target lesion revascularization. The secondary end-point was 2-year target lesion failure (TLF).
Results:
There were no significant differences in baseline characteristics, except that the patients with EES had a significantly higher prevalence of diabetes mellitus (34.7 vs. 22.7%, p = 0.002) and were older (67.1 ± 11.3 vs. 64 ± 12.9 years, p = 0.039) compared with the patients with BES. After propensity score matching, 2-year clinical outcomes showed no differences in composite MACEs or TLF between the two groups. Multivariate Cox regression analysis showed that stent type was not a predictor of 2-year mortality or MACEs. However, older age (hazard ratio [HR] 1.037, 95% confidence interval [CI] 1.014-1.060, p = 0.001), diabetes mellitus (HR 2.247, 95% CI 1.426-3.539, p = 0.001) and a left ventricular ejection fraction ≤ 45% (HR 3.007, 95% CI 1.978-4.573, p = 0.001) were independent predictors for 2-year MACEs in patients undergoing EES or BES.
Conclusions:
Patients with BES had similar clinical 2-year outcomes compared with EES patients with AMI.